Human sRAGE Protein for Treating Vascular Disease, Injury, or InflammationMethods of producing soluble receptors for advanced glycation end products (sRAGE) with enhanced expression, the resulting modified molecules, and methods of using this highly potent sRAGE for treating adverse vascular conditions. The inventors established a way to produce human sRAGE with more than 1000-fold greater potency than current methods. Production of full length human sRAGE in cultured mammalian cells enables the addition of mammalian post-translational modifications that dramatically enhance potency.
The receptor for advanced glycation end products (RAGE) is a cell surface protein that triggers signaling pathways leading to inflammation. RAGE-stimulated inflammation can contribute to adverse vascular conditions, such as atherosclerosis and restenosis. The soluble version of RAGE (sRAGE) binds the same target molecules (advanced glycation end products), but cannot activate inflammatory signaling pathways. For this reason, sRAGE is thought to act as a decoy for RAGE. sRAGE reduces inflammation and pathogenic consequences associated with RAGE signaling.
Source:
Human sRAGE Protein for Treating Vascular Disease, Injury, or InflammationLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=65265.0
